Advertisement

Tumor Biology

, Volume 37, Issue 8, pp 10415–10426 | Cite as

Hyperthermotherapy enhances antitumor effect of 5-aminolevulinic acid-mediated sonodynamic therapy with activation of caspase-dependent apoptotic pathway in human glioma

  • Donghui Ju
  • Fumio Yamaguchi
  • Guangzhi Zhan
  • Tadashi Higuchi
  • Takayuki Asakura
  • Akio Morita
  • Hideo Orimo
  • Shaoshan Hu
Original Article

Abstract

Sonodynamic therapy (SDT) has shown great potential as an approach for cancer treatment, and hyperthermotherapy (HT) is also a promising cancer therapy. Here, we investigate whether HT could improve the efficacy of SDT and to make a preliminary exploration on potential mechanism. Xenograft tumor was established in nude mice model, and SNB19 and U87MG glioma cell lines were utilized for in vitro experiment. Alamar blue assay was performed to assess cell viability. Optical microscope was used to characterize the morphology changes of the glioma cells induced by SDT and HT treatments. Apoptotic rate, mitochondrial membrane potential (MMP), and intracellular production of reactive oxygen species (ROS) were examined by flow cytometer. The cell apoptosis of tumor tissues were detected by TUNEL assay. Furthermore, the expression of apoptosis-related proteins was detected with Western blot in vitro and immunohistochemistry in vivo. SDT plus HT group could significantly reduce the cell viability with circular-cell morphological change, compared with SDT group, and cell viability was decreased depending on raise of 5-ALA concentration, ultrasound exposure time, and temperature. The results also indicate that HT increased a conspicuous apoptosis, ROS production, and a remarkable loss in MMP induced by 5-ALA-SDT in vitro. Meanwhile, our data also demonstrated that the combined treatment could significantly induce apoptosis and delay tumor growth in vivo. Furthermore, in both in vitro and in vivo experiments, SDT plus HT group expressed significantly higher protein levels of Bax and cleaved caspase-3, 8, and 9 compared to SDT, HT, and control groups and significantly lower protein level of bcl-2 than the other three groups, while the expression of these proteins was unchanged between HT and control groups. HT may provide an important promotion on 5-ALA-SDT and further propose that SDT in combination with HT is a new potential application for the treatment of human glioma.

Keywords

Sonodynamic therapy 5-aminolevulinic acid Hyperthermotherapy Antitumor effect Apoptosis Glioma 

Notes

Acknowledgments

We are grateful to Atsushi Chuma, Ito Co., LTD. for kindly providing ultrasonic apparatus. Miyuki Takatori and Kiyomi Kikukawa, Research Center for Life Science, Nippon Medical School, provided technical supports for the flow-cytometric analysis. We are also grateful to Ying Hu, School of Life Science and Technology, Harbin Institute of Technology, for providing technical assistance. This work was partly supported by Grant-in-Aid for challenging Exploratory Research from JSPS KAKENHI grant number 25670626 to FY. In addition, this work was also supported by grants from the Science and Technology Cooperation Project Foundation of Heilongjiang Medical Science Institute (ys14c11).

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63–82.CrossRefPubMedGoogle Scholar
  2. 2.
    Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507.CrossRefPubMedGoogle Scholar
  3. 3.
    Paw I, Carpenter RC, Watabe K, Debinski W, Lo HW. Mechanisms regulating glioma invasion. Cancer Lett. 2015;362(1):1–7.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gállego Pérez-Larraya J, Delattre JY. Management of elderly patients with gliomas. Oncologist. 2014;19(12):1258–67.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas—a clinical review of three selected approaches. Pharmacol Ther. 2013;139(3):341–58.CrossRefPubMedGoogle Scholar
  6. 6.
    Arrillaga-Romany I, Reardon DA, Wen PY. Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014;23(2):199–210.CrossRefPubMedGoogle Scholar
  7. 7.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.CrossRefPubMedGoogle Scholar
  8. 8.
    Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperth. 2001;17(1):1–18.CrossRefGoogle Scholar
  9. 9.
    Yi GQ, Gu B, Chen LK. The safety and efficacy of magnetic nano-iron hyperthermia therapy on rat brain glioma. Tumor Biol. 2014;35(3):2445–9.CrossRefGoogle Scholar
  10. 10.
    Otte J. Hyperthermia in cancer therapy. Eur J Pediatr. 1988;147(6):560–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Toraya-Brown S, Fiering S. Local tumor hyperthermia as immunotherapy for metastatic cancer. Int J Hyperth. 2014;30(8):531–9.CrossRefGoogle Scholar
  12. 12.
    Müller S. Magnetic fluid hyperthermia therapy for malignant brain tumors—an ethical discussion. Nanomedicine. 2009;5(4):387–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Mallory M, Gogineni E, Jones GC, Greer L, Simone CB 2nd. Therapeutic hyperthermia: The old, the new, and the upcoming. Crit Rev Oncol Hematol. 2015. doi: 10.1016/j.critrevonc.2015.08.003.
  14. 14.
    Rao W, Deng ZS, Liu J. A review of hyperthermia combined with radiotherapy/chemotherapy on malignant tumors. Crit Rev Biomed Eng. 2010;38(1):101–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Inoue H, Kajimoto Y, Shibata MA, Miyoshi N, Ogawa N, Miyatake S, et al. Massive apoptotic cell death of human glioma cells via a mitochondrial pathway following 5-aminolevulinic acid-mediated photodynamic therapy. J Neurooncol. 2007;83(3):223–31.CrossRefPubMedGoogle Scholar
  16. 16.
    Krammer B, Plaetzer K. ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci. 2008;7(3):283–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Gao Z, Zheng J, Yang B, Wang Z, Fan H, Lv Y, et al. Sonodynamic therapy inhibits angiogenesis and tumor growth in a xenograft mouse model. Cancer Lett. 2013;335(1):93–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Yamaguchi F, Asakura T, Takahashi H, Kitamura T, Teramoto A. Low frequency ultrasonication induced antitumor effect in 5-Aminolevulinic acid treated malignant glioma. J Cancer Ther. 2013;4(1):170–5.CrossRefGoogle Scholar
  19. 19.
    Umemura S, Yumita N, Nishigaki R, Umemura K. Mechanism of cell damage by ultrasound in combination with hematoporphyrin. Jpn J Cancer Res. 1990;81(9):962–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Tsuru H, Shibaguchi H, Kuroki M, Yamashita Y, Kuroki M. Tumor growth inhibition by sonodynamic therapy using a novel sonosensitizer. Free Radic Biol Med. 2012;53(3):464–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Song W, Cui H, Zhang R, Zheng J, Cao W. Apoptosis of SAS cells induced by sonodynamic therapy using 5-aminolevulinic acid sonosensitizer. Anticancer Res. 2011;31(1):39–45.PubMedGoogle Scholar
  22. 22.
    Wang H, Wang X, Zhang S, Wang P, Zhang K, Liu Q. Sinoporphyrin sodium, a novel sensitizer, triggers mitochondrial-dependent apoptosis in ECA-109 cells via production of reactive oxygen species. Int J Nanomedicine. 2014;9:3077–90.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    McEwan C, Owen J, Stride E, Fowley C, Nesbitt H, Cochrane D, et al. Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumors. J Control Release. 2015;203:51–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Gross JL, Behrens DL, Mullins DE, Kornblith PL, Dexter DL. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res. 1988;48(2):291–6.PubMedGoogle Scholar
  25. 25.
    Teng L, Nakada M, Zhao SG, Endo Y, Furuyama N, Nambu E, et al. Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy. Br J Cancer. 2011;104(5):798–807.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wang X, Jia Y, Su X, Wang P, Zhang K, Feng X, et al. Combination of protoporphyrin IX-mediated sonodynamic treatment with doxorubicin synergistically induced apoptotic cell death of a multidrug-resistant Leukemia K562/DOX cell line. Ultrasound Med Biol. 2015;41(10):2731–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Canaparo R, Varchi G, Ballestri M, Foglietta F, Sotgiu G, Guerrini A, et al. Polymeric nanoparticles enhance the sonodynamic activity of meso-tetrakis (4-sulfonatophenyl) porphyrin in an vitro neuroblastoma model. Int J Nanomedicine. 2013;8:4247–63.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Xiang J, Xia X, Jiang Y, Leung AW, Wang X, Xu J, et al. Apoptosis of ovarian cancer cells induced by methylene blue-mediated sonodynamic action. Ultrasonics. 2011;51(3):390–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Dereski MO, Madigan L, Chopp M. The effect of hypothermia and hyperthermia on photodynamic therapy of normal brain. Neurosurgery. 1995;36(1):141–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Chen B, Roskams T, de Witte PA. Enhancing the antitumoral effect of hypericin-mediated photodynamic therapy by hyperthermia. Lasers Surg Med. 2002;31(3):158–63.CrossRefPubMedGoogle Scholar
  31. 31.
    Lopez J, Tait SW. Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer. 2015;112(6):957–62.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis. 2003;8(2):115–28.CrossRefPubMedGoogle Scholar
  33. 33.
    Suski JM, Lebiedzinska M, Bonora M, Pinton P, Duszynski J, Wieckowski MR. Relation between mitochondrial membrane potential and ROS formation. Methods Mol Biol. 2012;810:183–205.CrossRefPubMedGoogle Scholar
  34. 34.
    Gomez-Cabrera MC, Sanchis-Gomar F, Garcia-Valles R, Pareja-Galeano H, Gambini J, Borras C, et al. Mitochondria as sources and targets of damage in cellular aging. Clin Chem Lab Med. 2012;50(8):1287–95.CrossRefPubMedGoogle Scholar
  35. 35.
    Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell. 2006;10(3):241–52.CrossRefPubMedGoogle Scholar
  36. 36.
    Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47–95.CrossRefPubMedGoogle Scholar
  37. 37.
    Trendowski M. The inherent metastasis of leukaemia and its exploitation by sonodynamic therapy. Crit Rev Oncol Hematol. 2015;94(2):149–63.CrossRefPubMedGoogle Scholar
  38. 38.
    Banerjee Mustafi S, Chakraborty PK, Dey RS, Raha S. Heat stress upregulates chaperone heat shock protein 70 and antioxidant manganese superoxide dismutase through reactive oxygen species (ROS), p38MAPK, and Akt. Cell Stress Chaperones. 2009;14(6):579–89.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Zhang HJ, Xu L, Drake VJ, Xie L, Oberley LW, Kregel KC. Heat-induced liver injury in old rats is associated with exaggerated oxidative stress and altered transcription factor activation. FASEB J. 2003;17(15):2293–5.PubMedGoogle Scholar
  40. 40.
    Pallepati P, Averill-Bates DA. Mild thermotolerance induced at 40°C protects HeLa cells against activation of death receptor-mediated apoptosis by hydrogen peroxide. Free Radic Biol Med. 2011;50(6):667–79.CrossRefPubMedGoogle Scholar
  41. 41.
    Breckenridge DG, Xue D. Regulation of mitochondrial membrane permeabilization by Bcl-2 family proteins and caspases. Curr Opin Cell Biol. 2004;16(6):647–52.CrossRefPubMedGoogle Scholar
  42. 42.
    Schwarz CS, Evert BO, Seyfried J, Schaupp M, Kunz WS, Vielhaber S, et al. Overexpression of bcl-2 results in reduction of cytochrome c content and inhibition of complex I activity. Biochem Biophys Res Commun. 2001;280(4):1021–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Donghui Ju
    • 1
    • 2
  • Fumio Yamaguchi
    • 2
  • Guangzhi Zhan
    • 2
  • Tadashi Higuchi
    • 2
  • Takayuki Asakura
    • 2
  • Akio Morita
    • 2
  • Hideo Orimo
    • 3
  • Shaoshan Hu
    • 1
  1. 1.Department of NeurosurgeryThe Second Affiliated Hospital of Harbin Medical UniversityHarbinChina
  2. 2.Department of Neurological SurgeryNippon Medical SchoolTokyoJapan
  3. 3.Division of Metabolism and Nutrition, Department of Biochemistry and Molecular BiologyNippon Medical SchoolTokyoJapan

Personalised recommendations